Researchers have identified a three-gene blood panel that distinguishes patients with non-tuberculous mycobacterial pulmonary disease from healthy controls with high accuracy. Published in BMC Infectious Diseases, the study leverages transcriptomic profiling to address the limitations of current diagnostic methods, which rely heavily on microbiological culture and species identification. These traditional approaches are often constrained by prolonged turnaround times, typically ranging from three to six weeks, and limited sensitivity. The new biomarker panel offers a rapid, minimally invasive alternative that could streamline the diagnostic process for this increasingly common respiratory condition.
The global incidence of non-tuberculous mycobacterial pulmonary disease has surged in recent decades, establishing it as a formidable challenge in respiratory medicine. Despite its escalating clinical burden, the lack of rapid diagnostic tools remains a significant hurdle for clinicians. The study aimed to identify and validate peripheral blood mRNA signatures as non-invasive diagnostic biomarkers.
The study employed a two-phase design to ensure the robustness of the findings. In the discovery phase, the team recruited 28 participants, comprising eight patients with Mycobacterium abscessus pulmonary disease, eight patients with Mycobacterium avium complex pulmonary disease, and twelve age and sex-matched healthy controls. Peripheral blood samples from all participants underwent bulk RNA sequencing and single-cell transcriptome sequencing.
Hub genes prioritized through integrated bioinformatics analysis were subsequently validated in an expanded cohort. The validation phase included 50 patients with non-tuberculous mycobacterial pulmonary disease, consisting of 23 with Mycobacterium avium complex disease and 27 with Mycobacterium abscessus disease, along with 35 healthy controls. The team used quantitative reverse transcription PCR to confirm the expression levels of the candidate genes.
Transcriptomic profiling revealed significant upregulation of eight core genes in patients with non-tuberculous mycobacterial pulmonary disease compared to healthy controls. These genes included IFIT1, IFI44L, GBP5, FOLR3, LY6E, IFITM1, S100A8, and S100A12. Among these, four genes exhibited the most pronounced differential expression: IFIT1, IFITM1, S100A12, and GBP5.
Single-cell transcriptomic analysis further confirmed that these hub genes were predominantly upregulated in monocyte/macrophage and neutrophil subpopulations. This cellular resolution validated the bulk-level findings and provided insight into the specific immune cell types driving the observed gene expression changes.
Receiver operating characteristic curve analysis identified the triple-gene panel of IFITM1, S100A12, and GBP5 as the optimal diagnostic signature. This combination achieved an area under the curve of 0.85, with a sensitivity of 84% and a specificity of 78%. These metrics indicate that the panel significantly outperforms other candidate combinations in distinguishing between patients and healthy controls.
The study concludes that the integration of bulk RNA sequencing discovery with single-cell sequencing validation has yielded a robust diagnostic tool. The three-gene panel offers a rapid, minimally invasive diagnostic option with the potential to transform clinical practice, particularly in resource-limited settings where conventional microbiological methods remain challenging.
Subject of Research: Development of a blood-based gene expression panel for diagnosing non-tuberculous mycobacterial pulmonary disease
Article Title: Blood transcriptomic profiling identifies hub genes with diagnostic and clinical relevance in non-tuberculous mycobacterial pulmonary disease
Article References: Yang, G.-L., Wang, L., Zeng, W.-Q., Zheng, X.-B., Yao, L., Chen, J.-X., & Sha, W. (2026). Blood transcriptomic profiling identifies hub genes with diagnostic and clinical relevance in non-tuberculous mycobacterial pulmonary disease. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14281-8
https://bioengineer.org/blood-gene-panel-detects-non-tuberculous-mycobacterial-lung-disease/
